NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Firm”), a late-stage medical biopharmaceutical firm targeted on the event of novel therapies for a broad vary of most cancers indications, at this time introduced that the European Fee, primarily based on a constructive opinion issued by the European Medicines Company (EMA), has granted Orphan Drug Designation (ODD) for SLS009, a novel, and extremely selective CDK9 inhibitor, for the remedy of acute myeloid leukemia (AML).
“We’re thrilled to obtain ODD from the EMA for the remedy of AML. This designation together with the lately introduced robust preliminary Section 2 information and former FDA ODD designation reinforces our continued progress and dedication to creating SLS009 as a possible remedy for AML,” mentioned Angelos Stergiou, MD, ScD h.c., President and Chief Govt Officer of SELLAS. “We sit up for working intently with the EMA and the FDA to advance SLS009 medical growth and finally ship it to the sufferers who want it most. To that finish, we stay on observe to share additional information round SLS009 within the third quarter of this yr.”
Orphan drug designation within the European Union (EU) is granted by the European Fee primarily based on a constructive opinion issued by the European Medical Affiliation (EMA) Committee for Orphan Medicinal Merchandise. The EMA’s orphan designation is accessible to firms creating therapies for life-threatening or chronically debilitating circumstances that have an effect on fewer than 5 in 10,000 individuals within the EU. Medicines that meet the EMA’s orphan designation standards qualify for monetary and regulatory incentives that embrace a 10-year interval of selling exclusivity within the EU after product approval, protocol help from the EMA at diminished charges in the course of the product growth section, and entry to centralized advertising and marketing authorization. The remedy should additionally present vital profit to these affected by the situation.
“We’re excited to obtain this designation from the EMA to enhance the sooner FDA’s ODD. The continued medical trial information continues to assist vital profit in sufferers with AML relapsed after or refractory to venetoclax regimens and the EMA acknowledges the numerous advantage of SLS009 for sufferers impacted by AML. Along with EMA’s Protocol Help will outline a path to an eventual regulatory approval within the European Union and dealing with the FDA in direction of a possible approval within the US,” mentioned Andrew Elnatan, Vice President of Regulatory Affairs at SELLAS.
The Section 2a medical trial of SLS009 is an open-label, single-arm, multi-center research designed to guage the security, tolerability, and efficacy of SLS009 together with aza/ven at two dose ranges, 45 and 60 mg. Within the 60 mg dose cohort sufferers had been randomized into both a 60 mg dose as soon as per week or a 30 mg dose two instances per week. The goal response charge on the optimum dose stage is 20% with a goal median survival over 3 months. ASXL1 mutation has been recognized as essentially the most promising goal mutation primarily based on biology of the mutation and the SLS009 mechanism of motion that has been confirmed by the medical outcomes thus far. The trial continues enrollment in two cohorts, each enrolling sufferers with myelodysplasia-related mutations, one with ASXL1 mutations and the opposite with myelodysplasia-related mutations aside from ASXL1. For extra data on the research, go to clinicaltrial.gov identifier NCT04588922.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage medical biopharmaceutical firm targeted on the event of novel therapeutics for a broad vary of most cancers indications. SELLAS’ different lead product candidate, GPS, is licensed from Memorial Sloan Kettering Most cancers Heart and targets the WT1 protein, which is current in an array of tumor sorts. GPS has the potential as a monotherapy and mixture with different therapies to deal with a broad spectrum of hematologic malignancies and stable tumor indications. The Firm can be creating SLS009 (previously GFH009) – probably the primary and best-in-class differentiated small molecule CDK9 inhibitor with diminished toxicity and elevated efficiency in comparison with different CDK9 inhibitors. Information means that SLS009 demonstrated a excessive response charge in AML sufferers with unfavorable prognostic components together with ASXL1 mutation, generally related to poor prognosis in numerous myeloid ailments. For extra data on SELLAS, please go to www.sellaslifesciences.com.
Ahead-Wanting Statements
This press launch comprises forward-looking statements. All statements aside from statements of historic information are “forward-looking statements,” together with these regarding future occasions. In some instances, forward-looking statements could be recognized by terminology resembling “plan,” “count on,” “anticipate,” “might,” “may,” “will,” “ought to,” “mission,” “consider,” “estimate,” “predict,” “potential,” “intend,” or “proceed” and different phrases or phrases of comparable that means. These statements embrace, with out limitation, statements associated to the SLS009 medical growth program, together with information therefrom, and regulatory technique. These forward-looking statements are primarily based on present plans, aims, estimates, expectations, and intentions, and inherently contain vital dangers and uncertainties. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of these dangers and uncertainties, which embrace, with out limitation, dangers and uncertainties with oncology product growth and medical success thereof, the uncertainty of regulatory approval, and different dangers and uncertainties affecting SELLAS and its growth packages as set forth underneath the caption “Threat Elements” in SELLAS’ Annual Report on Kind 10-Ok filed on March 28, 2024 and in its different SEC filings. Different dangers and uncertainties of which SELLAS is just not presently conscious might also have an effect on SELLAS’ forward-looking statements and will trigger precise outcomes and the timing of occasions to vary materially from these anticipated. The forward-looking statements herein are made solely as of the date hereof. SELLAS undertakes no obligation to replace or complement any forward-looking statements to replicate precise outcomes, new data, future occasions, adjustments in its expectations or different circumstances that exist after the date as of which the forward-looking statements had been made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
____________________
References:
1. European Medicines Company (2023). “Orphan Designation.” https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
